14.70
+0(+0.00%)
Currency In USD
| Previous Close | 14.7 |
| Open | 14.72 |
| Day High | 14.73 |
| Day Low | 14.67 |
| 52-Week High | 15.06 |
| 52-Week Low | 4.16 |
| Volume | 7.09M |
| Average Volume | 3.88M |
| Market Cap | 2.18B |
| PE | -3.98 |
| EPS | -3.69 |
| Moving Average 50 Days | 10.13 |
| Moving Average 200 Days | 9 |
| Change | 0 |
If you invested $1000 in 89bio, Inc. (ETNB) since IPO date, it would be worth $706.73 as of October 01, 2025 at a share price of $14.7. Whereas If you bought $1000 worth of 89bio, Inc. (ETNB) shares 5 years ago, it would be worth $583.1 as of October 01, 2025 at a share price of $14.7.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
89bio, Inc. Announces Agreement to be Acquired by Roche
GlobeNewswire Inc.
Sep 18, 2025 5:02 AM GMT
– 89bio stockholders to receive up to $20.50 per share in cash, comprised of $14.50 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $6.00 per share in cash; transaction represents total e
89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
GlobeNewswire Inc.
Jun 04, 2025 8:05 PM GMT
SAN FRANCISCO, June 04, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver a
89bio to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
May 06, 2025 8:05 PM GMT
SAN FRANCISCO, May 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver an